Search

Your search keyword '"Cavender, Matthew A."' showing total 21 results
Start Over Author "Cavender, Matthew A." Journal circulation
21 results on '"Cavender, Matthew A."'

1. Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial

Author

Tannu, Manasi, Kaltenbach, Lisa, Pagidipati, Neha J., McGuire, Darren K., Aroda, Vanita R., Pop-Busui, Rodica, Kondamudi, Nitin, Al-Khalidi, Hussein R., Lopes, Renato D., Cavender, Matthew A., Nelson, Adam J., Kirk, Julienne, Lingvay, Ildiko, Magwire, Melissa, Richardson, Caroline Regina, Webb, Laura, Leyva, Monica, Pandey, Ambarish, Washington, Alana, Pak, Jonathan, Gaynor, Tanya, Khan, Waqar, Weston, Patrick, Granger, Christopher B., and Green, Jennifer

Published
2024
Full Text
View/download PDF

3. Response by Kosiborod et al to Letters Regarding Article, “Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)”

Author

Kosiborod, Mikhail, Cavender, Matthew A., Fu, Alex Z., Wilding, John P., Khunti, Kamlesh, Holl, Reinhard W., Norhammar, Anna, Birkeland, Kåre I., Jørgensen, Marit Eika, Thuresson, Marcus, Arya, Niki, Bodegård, Johan, Hammar, Niklas, and Fenici, Peter

Published
2018
Full Text
View/download PDF

6. Abstract 10159: Underuse of Evidence-based Therapies for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease: Insights from Clinical Research Networks in the United States

Author

Nelson, Adam J, primary, O'Brien, Emily, additional, Kaltenbach, Lisa A, additional, Green, Jennifer, additional, Lopes, Renato D, additional, Morse, Caryn G, additional, Al-khalidi, Hussein, additional, Aroda, Vanita, additional, Cavender, Matthew A, additional, Gaynor, Tanya, additional, Kirk, Julienne, additional, Lingvay, Ildiko, additional, magwire, melissa, additional, McGuire, Darren K, additional, Pak, Jonathan, additional, Pop-Busui, Rodica, additional, Richardson, Caroline, additional, Senyucel, Cagri, additional, Kelsey, Michelle, additional, Pagidipati, Neha J, additional, and Granger, Christopher B, additional

Published
2021
Full Text
View/download PDF

7. Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community

Author

Nelson, Adam J., primary, Pagidipati, Neha J., additional, Aroda, Vanita R., additional, Cavender, Matthew A., additional, Green, Jennifer B., additional, Lopes, Renato D., additional, Al-Khalidi, Hussein, additional, Gaynor, Tanya, additional, Kaltenbach, Lisa A., additional, Kirk, Julienne K., additional, Lingvay, Ildiko, additional, Magwire, Melissa L., additional, O’Brien, Emily C., additional, Pak, Jonathan, additional, Pop-Busui, Rodica, additional, Richardson, Caroline R., additional, Reed, Monica, additional, Senyucel, Cagri, additional, Webb, Laura, additional, McGuire, Darren K., additional, and Granger, Christopher B., additional

Published
2021
Full Text
View/download PDF

8. Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions

Author

Hamm, Christian W., Price, Matthew J., Harrington, Robert A., Bhatt, Deepak L., Prats, Jayne, Mahaffey, Kenneth W., Cavender, Matthew A., Gibson, C. Michael, Stone, Gregg W., Leonardi, Sergio, Deliargyris, Efthymios N., White, Harvey D., and Steg, Ph. Gabriel

Subjects
Male, Ticlopidine, percutaneous coronary intervention, Myocardial Infarction, Disease Management, Middle Aged, Adenosine Monophosphate, Perioperative Care, Clopidogrel, Double-Blind Method, Original Research Articles, creatine kinase, MB form, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, Purinergic P2Y Receptor Antagonists, Humans, Female, Infusions, Intravenous, Platelet Aggregation Inhibitors, Aged
Abstract

Supplemental Digital Content is available in the text., BACKGROUND: Cangrelor is an intravenous P2Y12 inhibitor approved to reduce periprocedural ischemic events in patients undergoing percutaneous coronary intervention not pretreated with a P2Y12 inhibitor. METHODS: A total of 11 145 patients were randomized to cangrelor or clopidogrel in the CHAMPION PHOENIX trial (Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). We explored the effects of cangrelor on myocardial infarction (MI) using different definitions and performed sensitivity analyses on the primary end point of the trial. RESULTS: A total of 462 patients (4.2%) undergoing percutaneous coronary intervention had an MI as defined by the second universal definition. The majority of these MIs (n=433, 93.7%) were type 4a. Treatment with cangrelor reduced the incidence of MI at 48 hours (3.8% versus 4.7%; odds ratio [OR], 0.80; 95% confidence interval [CI], 0.67–0.97; P=0.02). When the Society of Coronary Angiography and Intervention definition of periprocedural MI was applied to potential ischemic events, there were fewer total MIs (n=134); however, the effects of cangrelor on MI remained significant (OR, 0.65; 95% CI, 0.46–0.92; P=0.01). Similar effects were seen in the evaluation of the effects of cangrelor on MIs with peak creatinine kinase-MB ≥10 times the upper limit of normal (OR, 0.64; 95% CI, 0.45–0.91) and those with peak creatinine kinase-MB ≥10 times the upper limit of normal, ischemic symptoms, or ECG changes (OR, 0.63; 95% CI, 0.48–0.84). MIs defined by any of these definitions were associated with increased risk of death at 30 days. Treatment with cangrelor reduced the composite end point of death, MI (Society of Coronary Angiography and Intervention definition), ischemia-driven revascularization, or Academic Research Consortium definite stent thrombosis (1.4% versus 2.1%; OR, 0.69; 95% CI, 0.51–0.92). CONCLUSIONS: MI in patients undergoing percutaneous coronary intervention, regardless of definition, remains associated with increased risk of death in the current era. Cangrelor compared with clopidogrel significantly reduces MI regardless of the definition. CLINICAL TRIAL REGISTRATION: URL: http://clinicaltrials.gov. Unique identifier: NCT01156571.

Published
2016

11. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs

Author

Kosiborod, Mikhail, primary, Cavender, Matthew A., additional, Fu, Alex Z., additional, Wilding, John P., additional, Khunti, Kamlesh, additional, Holl, Reinhard W., additional, Norhammar, Anna, additional, Birkeland, Kåre I., additional, Jørgensen, Marit Eika, additional, Thuresson, Marcus, additional, Arya, Niki, additional, Bodegård, Johan, additional, Hammar, Niklas, additional, and Fenici, Peter, additional

Published
2017
Full Text
View/download PDF

12. Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care)

Author

Cavender, Matthew A., primary, White, William B., additional, Jarolim, Petr, additional, Bakris, George L., additional, Cushman, William C., additional, Kupfer, Stuart, additional, Gao, Qi, additional, Mehta, Cyrus R., additional, Zannad, Faiez, additional, Cannon, Christopher P., additional, and Morrow, David A., additional

Published
2017
Full Text
View/download PDF

13. Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions

Author

Cavender, Matthew A., primary, Bhatt, Deepak L., additional, Stone, Gregg W., additional, White, Harvey D., additional, Steg, Ph. Gabriel, additional, Gibson, C. Michael, additional, Hamm, Christian W., additional, Price, Matthew J., additional, Leonardi, Sergio, additional, Prats, Jayne, additional, Deliargyris, Efthymios N., additional, Mahaffey, Kenneth W., additional, and Harrington, Robert A., additional

Published
2016
Full Text
View/download PDF

15. Response to Letter Regarding Article, “Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial”

Author

Scirica, Benjamin M., primary, Braunwald, Eugene, additional, Raz, Itamar, additional, Cavender, Matthew A., additional, Morrow, David A., additional, Jarolim, Petr, additional, Udell, Jacob A., additional, Mosenzon, Ofri, additional, Im, KyungAh, additional, Umez-Eronini, Amarachi A., additional, Pollack, Pia S., additional, Hirshberg, Boaz, additional, Frederich, Robert, additional, Lewis, Basil S., additional, McGuire, Darren K., additional, Davidson, Jaime, additional, Steg, Gabriel, additional, and Bhatt, Deepak L., additional

Published
2015
Full Text
View/download PDF

16. Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction

Author

Cavender, Matthew A., primary, Scirica, Benjamin M., additional, Bonaca, Marc P., additional, Angiolillo, Dominick J., additional, Dalby, Anthony J., additional, Dellborg, Mikael, additional, Morais, Joao, additional, Murphy, Sabina A., additional, Ophuis, Ton Oude, additional, Tendera, Michal, additional, Braunwald, Eugene, additional, and Morrow, David A., additional

Published
2015
Full Text
View/download PDF

17. Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial

Author

Scirica, Benjamin M., primary, Braunwald, Eugene, additional, Raz, Itamar, additional, Cavender, Matthew A., additional, Morrow, David A., additional, Jarolim, Petr, additional, Udell, Jacob A., additional, Mosenzon, Ofri, additional, Im, KyungAh, additional, Umez-Eronini, Amarachi A., additional, Pollack, Pia S., additional, Hirshberg, Boaz, additional, Frederich, Robert, additional, Lewis, Basil S., additional, McGuire, Darren K., additional, Davidson, Jaime, additional, Steg, Ph. Gabriel, additional, and Bhatt, Deepak L., additional

Published
2014
Full Text
View/download PDF

19. Abstract 12818: Characteristics and Outcomes of Patients Admitted with NSTEMI and Decreasing vs. Increasing Cardiac Troponin I: The Atherosclerosis Risk in Communities (ARIC) Study Community Surveillance.

Author

Arora, Sameer, Cavender, Matthew A, Chang, Patricia P, Qamar, Arman, Rosamond, Wayne D, Hall, Michael E, Rossi, Joseph S, Kaul, Prashant, and Caughey, Melissa C

Subjects
*TROPONIN I, *MYOCARDIAL infarction, *HOSPITAL mortality, *ATHEROSCLEROSIS
Abstract

Background: Increasing or decreasing patterns in cardiac troponin I (cTnI) may reveal different prognostic information in patients admitted with non ST-segment elevation myocardial infarction (NSTEMI). Methods: Since 1987, the ARIC Study has conducted community surveillance of acute MI. We limited our analysis to patients admitted with NSTEMI, who presented within 12 hours of out-of-hospital onset chest pain, an initially elevated cTnI, at least 2 serial troponins drawn the first day of hospitalization before any cardiac procedure, and a minimum change in cTnI of 0.02 ng/mL. Clinical characteristics, management and outcomes were compared among patients with decreasing vs. increasing cTnI, and weighted to account for the sampling design. Mortality models were adjusted for demographics, comorbidities, duration of symptoms, medications and revascularization. Results: From 1996 - 2014, 1,926 hospitalizations met our inclusion criteria. Increasing cTnI was observed in most (78%). Compared to increasing cTnI, those with decreasing cTnI were more often black and women; and less likely to receive non-aspirin antiplatelets (44% vs. 63%), lipid lowering agents (62% vs. 80%), or invasive angiography (38% vs. 64%). Aspirin and beta blockers were similarly administered, and in-hospital mortality was equivalent (3% vs. 3%). However, patients with a decreasing cTnI had twice the 28-day all-cause mortality (12% vs. 5%; P =0.01), which was more frequently due to non-cardiovascular causes (Figure). After adjustments, all-cause mortality remained significantly greater for patients with decreasing cTnI (RR=2.33 95% CI 1.00 - 4.94). Conclusion: Among NSTEMI patients with initially elevated cTnI, those with decreasing cTnI are less likely to be managed by evidence-based therapies and have greater mortality, primarily driven by non-cardiovascular causes. Whether these associations are attributable to type 2 MI or a subacute presentation merits further investigation. [ABSTRACT FROM AUTHOR]

Published
2018

20. Abstract 14202: The B enchmarking an O ral A nticoagulant T reatment Rate in Patients With Nonvalvular A trial F ibrillation (BOAT-AF) Study: A Prospective, Multicenter Study Evaluating Perspectives on Use of Oral Anticoagulation Using a Patient Survey and Clinical Review by the Treating Physician Among Patients Not Currently Treated With Oral Anticoagulation

Author

Cannon, MD, FAHA, FACC, Christopher P, Sutherland, Julie, Ehrlich, Clifford L, Bachireddy, Ravinder, Valentine, Michael, Smiley, Nasser, Hearne, Steven, Trebnick, April, Datta, Sudarshana, Jaffer, Sara, Tucker, Emily A, Thorpe, Fran, Cavender, Matthew A, Hsieh, Wen-Hua, Doros, Gheorghe, O'Hare, Ali W, Kalayci, Arzu, and Reynolds, Matthew

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results